{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-113275","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.022427+00:00","generated_at":"2026-05-22T11:16:44.200189+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aldeyra reproxalap meets primary endpoint in Phase 3 dry eye chamber trial; NDA resubmission planned mid-2025","bullets":["Reproxalap statistically superior to vehicle on ocular discomfort (LS mean diff -6.5, P=0.002) in Phase 3 chamber trial (n=58 per arm).","No notable baseline differences across treatment arms; Aldeyra believes data address FDA CRL from April 2025.","NDA resubmission anticipated mid-2025 pending Type A meeting; review expected six months.","A recent field trial was numerically supportive but did not reach statistical significance; will be submitted as supportive.","No safety signals or treatment-related discontinuations; reproxalap well tolerated in over 2,900 patients studied."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-113275","json":"https://secwatch.observer/filing/0001193125-25-113275.json","markdown":"https://secwatch.observer/filing/0001193125-25-113275.md","text":"https://secwatch.observer/filing/0001193125-25-113275.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000119312525113275/0001193125-25-113275-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000119312525113275/d941544d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T11:16:44.200189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}